Tag: GHRH 1-29 analog

  • Sermorelin

    GHRH 1-29 analog

    A 29-amino-acid synthetic fragment of GHRH (residues 1-29) used for growth hormone deficiency diagnosis and treatment.

    Abstract

    Sermorelin (GRF 1-29; CAS 86168-78-7; molecular weight 3357.93) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone releasing hormone (GHRH). The 1-29 fragment retains essentially all the GH-stimulating activity of full-length GHRH (44 residues) and was the basis for the FDA approval (under the trade name Geref) for GH deficiency in children. The brand-name product was discontinued in 2008 for commercial reasons; sermorelin is now compounded for clinical use in some jurisdictions and sold as a research chemical. The compound is administered subcutaneously and stimulates pituitary GH release through GHRH receptor activation, distinct from the ghrelin receptor agonism of GHRPs. Combination of sermorelin with a GHRP (ipamorelin, GHRP-2) produces synergistic GH release. Pharmacokinetics: plasma half-life 11 to 12 minutes; subcutaneous bioavailability good.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.